Procter & Gamble Co.Booming sales of tissues and...

BY THE NUMBERS

August 09, 1991

Procter & Gamble Co.

Booming sales of tissues and detergents in Europe and Japan fueled this Cincinnati-based consumer products conglomerate to a 7 percent jump in earnings in its fourth fiscal quarter, which ended June 30.

The owner of the Hunt Valley-based Noxell line of cosmetics said yesterday that U.S. sales and earnings rose modestly in its fiscal year, but profits from international operations increased 13 percent from the previous year.

Procter & Gamble said that its sales and profits in Europe were especially strong.

The company also owns a detergent factory in Baltimore.

Three months ended 6/30/91

............Revenue .............Net .. .. ... .. .. ..Share

..6,722,000,000 .. .. ..304,000,000 .. .. .. .. 0.76

'90 ..6,216,000,000 .. .. .. 284,000,000 .. .. .. .. 0.75

% change .. +8.1 .. .. .. .. .. +7.0 .. .. .. .. .. .. +1.3

Year ended 6/30/91

.. .. .. ..Revenue .. .. .. .. Net .. .. .. .. .. .. Share

'91.. .. 27,026,000,000 .. .. 1,773,000 .. .. .. .. 4.62

'90.. .. 24,081,000,000 .. .. 1,602,000 .. .. .. .. 4.27

% change .. +12.2 .. .. .. .. .. +10.7 .. .. .. .. .. +8.2

Crop Genetics Inc.

Crop Genetics Inc., a biological crop protection company based in Hanover, continued to post losses in the second quarter of this year, but at a reduced rate from the year before.

The company, which is not expected to turn a profit for several more years, lost $1,431,800, or 44 cents per share, compared with $1,644,500, or 35 cents per share, in the same quarter of 1990. The higher per-share loss for this year was the result of a $641,300 preferred stock dividend payout.

Revenues from sales were nil during the quarter because the only product the company has on the market now, disease-free sugar cane seed, is in demand only during the planting season.

However, total revenue for the quarter increased from $122,900 to $425,700 because of a higher return on investments.

Research and development costs grew to $1,450,900 fro$1,233,800 last year, but the company managed to cut its general and administrative costs from $407,600 to $285,800.

Three months ended 6/30/91

.. .. .. .. Revenue .. .. .. Net .. .. .. Share

'91.. .. .. 425,700 .. .. ..(1,431,800).. (0.44)

.. .. 122,900 .. .. ..(1,644,500)..(0.35)

% change .. +246.4 .. .. .. .. ..-- .. .. ..--

Six months ended 6/30/91

.. .. .. ..Revenue .. .. .. Net.. .. .. .. Share

'91.. .. ..1,027,500.. .. .(2,877,500).. ..(0.89)

'90.. .. ..269,200.. .. .. (3,418,900).. ..(0.73)

% change.. .. +281.6 .. .. .. -- .. .. .. .. --

MedImmune Inc.

This Gaithersburg-based biotechnology company reported strong results for the three-month period that just ended, the first quarter it has reported as a public company.

MedImmune said that it earned $1.2 million, or 8 cents a share, during the period that ended June 30, in contrast to a loss of $734,136, or 18 cents a share, a year ago.

Revenue jumped more than sixfold, to $4.5 million from $675,731 during last year's comparable quarter.

The company said that the period's results included $1.5 million in revenues from the shipment of CytoGam, a treatment for a common viral infection stemming from kidney transplants. Sales of CytoGam were slightly lower during the second quarter compared with the first three months of the year, the company said, because of the planned shutdown of its manufacturing facility for modifications to triple the production capacity.

The company said that its second-quarter results also included a $1.7-million lump-sum payment from Merck & Co. Inc., the New Jersey pharmaceuticals giant, for MedImmune's completion of the first phase of work in developing an AIDS vaccine.

MedImmune was founded in 1988 to develop and make vaccines and treatments for certain types of infectious diseases and cancers.

During the second quarter, the company completed its initial public offering of 2.875 million shares of common stock and 506,066 shares of preferred stock. The sale of stock resulted in proceeds of $29.1 million for the company.

Three months ended 6/30/90

.. .. .. .. Revenue .. .. .. Net .. .. Share

'91.. .. 4,538,002 .. .. ..1,197,493.. 0.08

'90.. .. 675,731.. .. .. ..(34,136).. 0.18)

% change..+71.6 .. .. .. .. -- .. .. ..--

Six months ended 6/30/90

.. .. .. Revenue .. .. .. .Net .. .. ..Share

'91 .. ..8,307,780 .. .. 1,504,395.. ..0.11

'90 .. ..1,366,268 .. .. (1,363,497).. (0.33)

% change.. +508.1 .. .. .. -- .. .. .. ..--

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.